{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:12:00Z","timestamp":1770837120407,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"suppl_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"DOI":"10.1093\/jac\/dkx308","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T12:11:24Z","timestamp":1503576684000},"page":"i43-i47","source":"Crossref","is-referenced-by-count":18,"title":["A \u2018shock and awe\u2019 thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium\u2013intracellulare complex disease"],"prefix":"10.1093","volume":"72","author":[{"given":"Shashikant","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devyani","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carleton M.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,9,11]]},"reference":[{"key":"key\n\t\t\t\t20171011220426_dkx308-B1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0272-5231(02)00019-9","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria","volume":"23","year":"2002","journal-title":"Clin Chest Med"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B3","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1055\/s-0028-1085708","article-title":"Diagnosis and treatment of infections due to Mycobacterium avium complex","volume":"29","year":"2008","journal-title":"Semin Respir Crit Care Med"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B4","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/jac\/dkx311","article-title":"Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium\u2013intracellulare complex disease","volume":"72","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B5","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1128\/AAC.05546-11","article-title":"The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance","volume":"56","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B6","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/AAC.02985-15","article-title":"Thioridazine as chemotherapy for Mycobacterium avium complex diseases","volume":"60","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B7","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1128\/AAC.01761-09","article-title":"Moxifloxacin pharmacokinetics\/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B8","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1128\/AAC.02854-15","article-title":"Azithromycin dose to maximize efficacy and suppress acquired drug resistance in pulmonary Mycobacterium avium disease","volume":"60","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B9","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1128\/AAC.01355-09","article-title":"Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B10"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B11","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1093\/cid\/ciw473","article-title":"Concentration-dependent synergy and antagonism of linezolid and moxifloxacin in the treatment of childhood tuberculosis: the dynamic duo","volume":"63","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B12","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1093\/cid\/ciw472","article-title":"A combination regimen design program based on pharmacodynamic target setting for childhood tuberculosis: design rules for the playground","volume":"63","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B13","doi-asserted-by":"crossref","first-page":"ii30","DOI":"10.1093\/jac\/dkx305","article-title":"Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease","volume":"72","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B14","doi-asserted-by":"crossref","first-page":"ii36","DOI":"10.1093\/jac\/dkx306","article-title":"The discovery of ceftazidime\/avibactam as an anti-Mycobacterium avium agent","volume":"72","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B15","doi-asserted-by":"crossref","first-page":"ii48","DOI":"10.1093\/jac\/dkx307","article-title":"A novel ceftazidime\/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease","volume":"72","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","year":"1995","journal-title":"Pharmacol Rev"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A three-dimensional model to analyze drug-drug interactions","volume":"14","year":"1990","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","year":"1939","journal-title":"Ann Appl Biol"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B19","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1093\/cid\/ciw483","article-title":"Optimal clinical doses of faropenem, linezolid, and moxifloxacin in children with disseminated tuberculosis: Goldilocks","volume":"63","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B20","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/cid\/ciw474","article-title":"A faropenem, linezolid, and moxifloxacin regimen for both drug susceptible and multidrug-resistant tuberculosis in children: FLAME path on the Milky Way","volume":"63","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171011220426_dkx308-B21","doi-asserted-by":"crossref","first-page":"ii20","DOI":"10.1093\/jac\/dkx303","article-title":"Failure of the azithromycin and ethambutol combination regimen in the hollow fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistance","volume":"72","year":"2017","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/suppl_2\/i43\/19733558\/dkx308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T01:24:35Z","timestamp":1750814675000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/72\/suppl_2\/i43\/4110807\/A-shock-and-awe-thioridazine-and-moxifloxacin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,1]]},"references-count":21,"journal-issue":{"issue":"suppl_2","published-online":{"date-parts":[[2017,9,11]]},"published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx308","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,9]]},"published":{"date-parts":[[2017,9,1]]}}}